标题：二仙汤加减联合芬吗通治疗对原发性卵巢功能不全患者生殖内分泌激素及卵巢体积的影响

      作者：魏少奔 1，王宇慧 2，武俊丽 3，孙晓盈 4，陈梦捷 1    1.西安市中医医院妇科，陕西 西安 710026；2.南京市中医院妇科，江苏 南京 210001；3.西安市雁塔区中医医院妇科，陕西 西安 710000；4.渭南职业技术学院医学院，陕西 渭南 714000

      卷次： 2023年34卷15期

      【摘要】 目的 探讨二仙汤加减联合芬吗通治疗对原发性卵巢功能不全(POI)患者生殖内分泌激素、卵巢体积的影响。方法 选取2019年12月至2021年12月期间西安市中医医院妇科收治的122例POI患者为研究对象，按随机数表法分为研究组和对照组，每组61例，对照组患者采用芬吗通治疗，研究组患者采用二仙汤加减联合芬吗通治疗，两组均持续治疗3个周期，1个周期为28 d。比较两组患者治疗前后的血清促卵泡素(FSH)、雌二醇(E2)、促黄体生成素(LH)水平、子宫内膜厚度及绝经指数，并统计两组患者治疗后的不良反应发生情况。结果 两组患者治疗后的 FSH、LH和 E2水平均得到不同程度改善，且研究组患者的 FSH、LH水平分别为(12.07±4.42) U/L、(6.57±0.56) U/L，明显低于对照组的(19.35±3.98) U/L、(8.41±0.66) U/L，E2为(122.34±12.34) pmol/L，明显高于对照组的(91.65±13.75) pmol/L，差异均有统计学意义(P<0.05)；两组患者治疗后的子宫内膜厚度均上升，绝经指数均下降，且研究组患者的子宫内膜厚度为(7.19±0.98) mm，明显厚于对照组的(6.11±0.81) mm，绝经指数为(9.19±1.24)分，明显低于对照组的(14.55±1.54)分，差异均有统计学意义(P<0.05)；研究组不良反应总发生率为13.11%，略低于对照组的18.03%，但差异无统计学意义(P>0.05)。结论 二仙汤加减联合芬吗通治疗POI可明显改善患者的卵巢体积和内分泌激素水平，且安全性高。
      【关键词】 原发性卵巢功能不全；二仙汤加减；芬吗通；生殖内分泌激素；卵巢体积
      【中图分类号】 R711.75 【文献标识码】 A 【文章编号】 1003—6350（2023）15—2177—04

Effect of modified Erxian Decoction combined with Femoston on the reproductive endocrine hormones andovarian volume in patients with primary ovarian insufficiency.
WEI Shao-ben 1, WANG Yu-hui 2, WU Jun-li 3, SUNXiao-ying 4, CHEN Meng-jie 1. 1. Department of Gynecology, Xi'an Hospital of Traditional Chinese Medicine, Xi'an 710026,Shaanxi, CHINA; 2. Department of Gynecology, Nanjing Hospital of Traditional Chinese Medicine, Nanjing 210001, Jiangsu,CHINA; 3. Department of Gynecology, Yanta District Hospital of Traditional Chinese Medicine, Xi'an 710000, Shaanxi,CHINA; 4. School of Medicine, Weinan Vocational and Technical College, Weinan 714000, Shaanxi, CHINA
【Abstract】 Objective To analyze the effect of modified Erxian decoction combined with Femoston on the re-productive endocrine hormones and ovarian volume in patients with primary ovarian insufficiency (POI). Methods Atotal of 122 patients with POI admitted to the Department of Gynecology, Xi'an Hospital of Traditional Chinese Medi-cine from December 2019 to December 2021 were selected and randomly divided into a study group (n=61, treated withmodified Erxian decoction combined with Femoston) and a control group (n=61, treated with Femoston). The treatmentlasted for 3 cycles, with 28 days as one cycle. The serum levels of follicle-stimulating hormone (FSH), estradiol (E2), lu-teinizing hormone (LH), endometrial thickness, and menopausal index before and after treatment were compared be-tween the two groups. The incidence of adverse reactions after treatment was calculated. Results After treatment, FSH,LH, and E2 levels were improved to varying degrees in the two groups. FSH and LH in the study group were significant-ly lower than those in the control group: (12.07±4.42) U/L vs (19.35±3.98) U/L, (6.57±0.56) U/L vs (8.41±0.66) U/L, andE2 in the study group were significantly higher: (122.34±12.34) vs (91.65±13.75), with statistically significant differenc-es (P<0.05). Endometrial thickness increased and menopause index decreased significantly in the two groups after treat-ment; endometrial thickness in the study group were significantly thicker than that in the control group: (7.19±0.98) mmvs (6.11±0.81) mm, and menopause index in the study group were significantly lower: (9.19±1.24) points vs (14.55±1.54) points, with statistically significant differences (P<0.05). The total incidence of adverse reactions in the studygroup (13.11%) was slightly lower than that in the control group (18.03%), and there was no statistically significant dif-ference between the two groups (P>0.05). Conclusion Modified Erxian decoction combined with Femoston can signif-icantly improve the ovarian volume and endocrine hormone levels in POI patients, and has high safety.
      【Key words】 Primary ovarian insufficiency; Modified Erxian Decoction; Femoston; Reproductive endocrine hor-mones; Ovary volume